Annual Industry Ranking And Forecast
VIEW NOWOutlook
2023
Jump To Section
Featured Stories

The 10 US Biosimilar Launches That Could Drive Big Savings By 2027
Biosimilar versions of drugs like Humira, Stelara and Eylea are among the products that could generate cumulative sales of $129bn over the next five years, according to IQVIA.

Novartis’s ‘Poster Child’ Zolgensma Shows What Gene Therapy Can Do – And Its Limitations
The clinical development head of Novartis Gene Therapies talks about the progress for SMA patients more than seven years after treatment began, and hopes of boosting outcomes by treating pre-symptomatic patients.

Gilead Waives Acquisition Option As Pionyr Explores Other Strategies
Gilead has waived its option to acquire Pionyr, allowing the US biotech to explore other partnerships and financing opportunities as it advances a promising pipeline of macrophage-targeting antibodies.
Asia Spotlight
As Japan’s Syphilis Cases Surge, So Do Calls For More Therapeutics
As Japan faces skyrocketing syphilis cases, hopes have been high among domestic physicians for a single-dose therapeutic in the form of benzylpenicillin injection. But the country has approved the drug only recently and in answer to a push from doctors on the front line.
Infographics

India M&As Overtook PE Activity In 2022, Deal Momentum To Continue In 2023
India had a busy deals calendar in 2022, with companies led by Biocon striking large M&A deals while PE activity declined. Scrip pieced together data for infographics on these deals. A multitude of factors is expected to keep the momentum going in 2023

The Deal Landscape At Mid-Year: Is Industry Following Through On Business Development Promises?
INFOGRAPHIC: Going into 2022, there were high expectations for deal-making, but industry continues to face significant headwinds. Scrip reviewed M&A and alliance activity for the first half of the year to track how business development is shaping up in 2022.

Titans Of Pharma 2022: Johnson & Johnson Pays Highest Exec Compensation Again
Infographic: A snapshot of executive compensation at the world’s biggest pharmaceutical companies. Explore our interactive dashboard and visualizations comparing remuneration packages with other key company metrics.
Commercial Explore this Topic
Remove Alert
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Commercial
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: ripples from SVB’s failure; Karuna’s schizophrenia win; big pharma remains open to partnering; ChatGPT comes to medical congresses; and China’s COVID vaccine lessons.
Finance Watch: Another VC Mega-Round As Flare Raises $123m Series B
Private Company Edition: Flare Therapeutics, targeting transcription factors to discover precision medicines, had big pharma backing for its second venture capital financing. Also, Mediar closed a $10m series A round, Switch launched with $52m and EpiBiologics raised a $50m series A round.
Chinese Biopharma Tycoons Down But Not Out In Latest Global Billionaire Ranking
China continues to dominate the latest list of global billionaires and top execs from domestic pharma firms Hengrui and Hansoh ranked among the wealthiest overall in the country, along with the founder of vaccine maker Zhifei Bio. A number of top Chinese biopharma business executives also featured in the global top 100 billionaires list.
Orange Grove CEO: Korean Opportunities A Priority In Global Expansion
US-based Orange Grove Bio inks first international partnerships with Korean universities, laying the foundation for its planned role as a bridge between the biotech industries in the two countries and to identify, develop and commercialize novel assets emerging from academic research.
Cidara’s Novel Antifungal Approved For Antimicrobial-Resistant C. Auris Infections
Cidara’s US commercial partner Melinta will launch the novel echinocandin this summer, announcing pricing shortly before rollout. Limited indication follows recommendation of FDA advisory panel.
PureTech Cashes In On Promise Of Karuna Schizophrenia Drug
Karuna’s KarXT could be the first new mechanism for treating schizophrenia approved in more than 50 years and founder PureTech is tapping into that promise by linking up with Royalty Pharma and boosting its cashpile.
Policy & Regulation Explore this Topic
Remove Alert
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Policy & Regulation
Incyte’s US Approval For PD-1 Inhibitor Zynyz In MCC Draws Muted Response
The US firm’s Zynyz has won accelerated approval for the treatment of first-line Merkel cell carcinoma, bouncing back from a prior regulatory setback, but its third-to-market status leaves it with the crumbs under the table in this orphan indication.
Pipeline Watch: Eight Approvals And 12 Phase III Trial Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Obstacle Thrown In Sarepta’s Path To Market As Gene Therapy Will Face AdComm After All
The route to market for Sarepta’s gene therapy candidate SRP-9001 for Duchenne muscular dystrophy has just got more complex after a U-turn by the US FDA. Its accelerated approval will now be scrutinized by outside experts – but the company remains confident in its data.
Research & Development
Remove Alert
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Research & Development
AbbVie’s Skyrizi Checks One Last Box With Phase III Success In Ulcerative Colitis
Already approved in Crohn’s disease, Skyrizi now has positive Phase III results in ulcerative colitis with more data expected this year in UC as the field grows more crowded with anti-IL-23 options.
Generation Bio’s LNP DNA-Delivery Platform Gets Big Boost From Moderna
The company aims to deliver DNA via lipid nanoparticles as well as delivering LNPs systemically to tissues beyond the liver and spleen, which the CEO called a “frontier” in an interview.
89bio’s Phase IIb Data Heighten Competition Within NASH FGF21 Analog Class
89bio’s pegozafermin met co-primary endpoints of fibrosis reduction and NASH resolution in Phase IIb; the company said its methodology yielded lower placebo responses than in Akero’s Phase IIb study.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.